miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis.
HALS (HIV-associate lypodistrophy syndrome)
combined highly antiretroviral therapy (cART)
metabolic disorders
miRNA
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Mar 2022
23 Mar 2022
Historique:
received:
21
02
2022
revised:
21
03
2022
accepted:
21
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Combined AntiRetroviral Treatments (cARTs) used for HIV infection may result in varied metabolic complications, which in some cases, may be related to patient genetic factors, particularly microRNAs. The use of monozygotic twins, differing only for HIV infection, presents a unique and powerful model for the controlled analysis of potential alterations of miRNAs regulation consequent to cART treatment. Profiling of 2578 mature miRNA in the subcutaneous (SC) adipose tissue and plasma of monozygotic twins was investigated by the GeneChip® miRNA 4.1 array. Real-time PCR and ddPCR experiments were performed in order to validate differentially expressed miRNAs. Target genes of deregulated miRNAs were predicted by the miRDB database (prediction score > 70) and enrichment analysis was carried out with g:Profiler. Processes in SC adipose tissue most greatly affected by miRNA up-regulation included (i) macromolecular metabolic processes, (ii) regulation of neurogenesis, and (iii) protein phosphorylation. Furthermore, KEGG analysis revealed miRNA up-regulation involvement in (i) insulin signaling pathways, (ii) neurotrophin signaling pathways, and (iii) pancreatic cancer. By contrast, miRNA up-regulation in plasma was involved in (i) melanoma, (ii) p53 signaling pathways, and (iii) focal adhesion. Our findings suggest a mechanism that may increase the predisposition of HIV+ patients to insulin resistance and cancer.
Identifiants
pubmed: 35408847
pii: ijms23073486
doi: 10.3390/ijms23073486
pmc: PMC8998861
pii:
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Brain Res. 2019 Apr 1;1708:100-108
pubmed: 30552897
Obesity (Silver Spring). 2017 Oct;25(10):1734-1744
pubmed: 28834285
J Thorac Dis. 2018 May;10(5):2599-2607
pubmed: 29997921
Front Pharmacol. 2019 Apr 30;10:461
pubmed: 31133852
J Cell Physiol. 2016 Jan;231(1):25-30
pubmed: 26031493
Adv Clin Chem. 2018;87:113-139
pubmed: 30342709
Int J Obes (Lond). 2017 Apr;41(4):620-630
pubmed: 28119530
Biochem Biophys Res Commun. 2011 Jan 7;404(1):16-22
pubmed: 21094635
J Clin Endocrinol Metab. 2016 Mar;101(3):1225-34
pubmed: 26756119
Metabolism. 2013 Sep;62(9):1199-205
pubmed: 23706880
Genes (Basel). 2019 Sep 28;10(10):
pubmed: 31569378
Nature. 2017 Feb 23;542(7642):450-455
pubmed: 28199304
Clin Chem. 2015 Nov;61(11):1333-42
pubmed: 26408530
Tumour Biol. 2015 Jan;36(1):437-46
pubmed: 25266797
Sci Rep. 2019 Oct 31;9(1):15735
pubmed: 31672997
Compr Physiol. 2017 Sep 12;7(4):1339-1357
pubmed: 28915327
Trends Endocrinol Metab. 2009 Nov;20(9):452-9
pubmed: 19800254
Exp Mol Med. 2018 Dec 26;50(12):1-12
pubmed: 30598522
Nat Cell Biol. 2011 Apr;13(4):423-33
pubmed: 21423178
EBioMedicine. 2019 May;43:307-316
pubmed: 31005516
J Antimicrob Chemother. 2014 Nov;69(11):3076-84
pubmed: 25185137
Front Mol Neurosci. 2019 Nov 22;12:283
pubmed: 31824261
Int J Mol Med. 2015 Nov;36(5):1400-8
pubmed: 26352225
F1000 Med Rep. 2010 Nov 24;2:83
pubmed: 21170375
Sci Rep. 2018 Jul 18;8(1):10875
pubmed: 30022109
J Antimicrob Chemother. 2014 Nov;69(11):3067-75
pubmed: 25063777
Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):907-11
pubmed: 20332265
Nat Commun. 2018 Apr 24;9(1):1614
pubmed: 29691399
Biochim Biophys Acta. 2010 Mar;1801(3):392-9
pubmed: 19800025
Clin Infect Dis. 2010 Nov 1;51(9):1090-8
pubmed: 20879858
Clin Exp Immunol. 2018 Sep;193(3):376-385
pubmed: 29892977
JCI Insight. 2021 Sep 22;6(18):
pubmed: 34383714
AIDS. 2013 Feb 20;27(4):529-38
pubmed: 23262498
Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1365-82
pubmed: 21999362
Biochem Biophys Res Commun. 2016 Apr 15;472(4):617-23
pubmed: 26966068
Antivir Ther. 2007;12(7):999-1013
pubmed: 18018758
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Sci Rep. 2018 Jun 29;8(1):9883
pubmed: 29959359
Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):487-99
pubmed: 21663842
J Clin Invest. 2014 Aug;124(8):3339-51
pubmed: 24983316
J Clin Virol. 2019 Aug;117:61-67
pubmed: 31229934
Retrovirology. 2008 Dec 29;5:118
pubmed: 19114009
J Cell Physiol. 2019 May;234(5):5496-5506
pubmed: 30246332
Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1926-1933
pubmed: 31488416
HIV Med. 2015 Sep;16(8):494-501
pubmed: 26111083
Sci Rep. 2019 Nov 20;9(1):17161
pubmed: 31748664
Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1212-1220
pubmed: 30988139
Diabetes. 2017 Feb;66(2):347-357
pubmed: 27899485
BMC Res Notes. 2016 Jan 22;9:38
pubmed: 26801621
Sci Rep. 2019 Aug 29;9(1):12507
pubmed: 31467339
PLoS One. 2013 Nov 05;8(11):e79652
pubmed: 24223986
PLoS Comput Biol. 2018 Jul 13;14(7):e1006185
pubmed: 30005074
Pharmacogenet Genomics. 2007 Sep;17(9):755-64
pubmed: 17700364
Ann Nutr Metab. 2015;66(1):10-8
pubmed: 25678092
Theranostics. 2015 Apr 05;5(7):733-45
pubmed: 25897338